5 key takeaways from Novavax’s Covid-19 vaccine hearing

The Gaithersburg biotech is now a step away from potentially getting its first product to market, after the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee gave its nod to Novavax’s experimental Covid-19 vaccine at its meeting Tuesday. The FDA, which typically listens to the advisory committee’s recommendations, must now decide whether to greenlight the protein-based shot for emergency use authorization for adults in the U.S. The Centers for Disease Control and Prevention would then have to endorse its use.